Insulin Types and Dosing Strategies

Table of Contents

  1. Why There Are So Many Insulins
  2. Rapid-Acting Bolus Insulins
  3. Ultra-Rapid and Inhaled
  4. Short-Acting (Regular) Insulin
  5. Intermediate — NPH
  6. Long-Acting Basal Insulins
  7. Premixed Insulins
  8. Pump-Compatible Insulins
  9. The Basal-Bolus MDI Regimen
  10. Pump Therapy and AID Systems
  11. Carb Counting Basics
  12. I:C Ratio, Correction Factor, and the 500/1800 Rules
  13. Basal Dosing and Basal Testing
  14. Dawn Phenomenon vs Somogyi
  15. Sick-Day Rules
  16. Exercise Adjustments
  17. Hypoglycemia Prevention in Brittle T1D
  18. Insurance and Cost Realities
  19. Key Research Papers
  20. Research Papers
  21. Connections

Why There Are So Many Insulins

A healthy pancreas releases insulin in two patterns. There is a slow background drip that runs twenty-four hours a day to keep the liver from dumping too much glucose into the blood, and there are fast bursts at every meal that shove dietary carbohydrate into muscle and fat cells. When you take insulin by injection, you are trying to recreate both of those patterns with products that come out of a vial. No single insulin can do both jobs well — fast and short for meals, slow and flat for background — so pharmaceutical companies have engineered a menu of molecules, each tuned to a different onset and duration. This article walks through every major category, how to choose between them, and how to dose them safely.

If you are new to insulin, the sheer number of names is intimidating. But the logic is simple: everything falls into one of five buckets — ultra-rapid, rapid, short, intermediate, long — plus premixed combinations. Once you understand the onset, peak, and duration of each bucket, the brand names stop mattering and you can speak fluently with your endocrinologist.

Rapid-Acting Bolus Insulins

Rapid-acting analogs are the workhorses of mealtime dosing. They appeared in the 1990s and replaced Regular insulin for most people because they match the speed of a carbohydrate meal far better. Three molecules share nearly identical pharmacology:

All three have an onset of roughly 15 minutes, a peak between 1 and 2 hours, and a total duration of 3 to 4 hours. In practice that means you inject 10 to 15 minutes before eating (not at the first bite) and the dose is mostly gone by the time you sit down to the next meal. The tail is short enough that stacking — giving a second dose before the first is finished — is less dangerous than with Regular insulin, but it is still the most common cause of unexpected lows.

There is no clinically important difference between Humalog, Novolog, and Apidra for most people. Choice is usually driven by insurance formulary, pump compatibility, or personal response. If one brand gives you site irritation or unpredictable absorption, switching is reasonable.

Ultra-Rapid and Inhaled

Two newer analogs squeeze the onset even shorter. Fiasp (faster-aspart) adds niacinamide to aspart, which speeds absorption. Lyumjev (ultra-rapid lispro) adds treprostinil and citrate, which dilate the capillary bed around the injection and pull the drug into circulation faster. Both have onsets around 3 to 5 minutes, with a peak roughly 30 minutes earlier than the older analogs.

The practical advantage is postprandial control — the 1- and 2-hour glucose after a meal. If your CGM traces show a big spike between eating and the two-hour mark even with pre-bolusing, switching to Fiasp or Lyumjev often flattens that curve. They also shine for people who cannot reliably pre-bolus (toddlers, people with gastroparesis, people who have to eat unpredictably at work).

Afrezza is inhaled human insulin powder. You load a single-use cartridge into a small inhaler and breathe the dose in at the start of a meal. Onset is about 12 minutes, peak 35 to 55 minutes, duration under 3 hours — the fastest clinically available insulin. It suits people who hate needles or want very tight postprandial numbers. Drawbacks: it comes only in 4-, 8-, and 12-unit cartridges (you round to the nearest cartridge), it requires a baseline pulmonary function test before starting, and it is not appropriate for smokers or people with asthma or COPD.

Short-Acting (Regular) Insulin

Regular insulin — also called R, Humulin R, or Novolin R — is plain recombinant human insulin. It has an onset of 30 minutes, peak at 2 to 4 hours, and duration of 6 to 8 hours. For decades it was the only mealtime option. Today it is mostly used for three reasons: cost, high-protein meals, and severe insulin resistance.

For cost: Walmart sells ReliOn Novolin R for about $25 a vial without a prescription in most U.S. states. Compared with $300 for a brand-name analog, that is life-saving for people without insurance, even though it is harder to use.

For high-protein meals: Regular's longer tail actually helps cover the delayed glucose rise from pizza, cheeseburgers, or a big steak dinner — the so-called "pizza effect," where dietary protein and fat slow carbohydrate absorption for hours. Some pump users run a "combo" or "dual-wave" bolus of rapid insulin, but a small dose of Regular in addition to rapid can do the same thing with a pen.

For severe insulin resistance: U-500 Regular insulin (Humulin R U-500) is five times more concentrated than standard U-100. It is reserved for people requiring more than about 200 units per day of total insulin, where U-100 volumes become impractical (imagine injecting 2 mL five times a day). U-500 dosing is a specialist-only territory because the timing and stacking behavior change — it behaves more like an intermediate than a true short-acting insulin.

Intermediate — NPH

NPH (Neutral Protamine Hagedorn) is Regular insulin mixed with a fish-sperm-derived protein that slows its release. Onset is 1 to 2 hours, peak 4 to 10 hours, duration 10 to 18 hours. It is cloudy — you have to roll the vial or pen between your palms to resuspend the crystals before drawing a dose.

NPH is the cheapest basal option — about $25 a vial at Walmart ReliOn — and still the global workhorse outside wealthy countries. The downside is the peak. A 10-hour peak means that if you take NPH at bedtime, you run a real risk of 3 a.m. hypoglycemia, and if you take it at breakfast you may crash in the late afternoon. Variability vial-to-vial and day-to-day is worse than with the true long-acting analogs.

For most insured patients, NPH has been replaced by glargine or degludec. For uninsured patients who cannot afford analogs, NPH plus Regular is a completely legitimate regimen — it is the regimen that kept people alive from the 1950s until the 1990s. It simply requires more discipline, more snacks, and more glucose monitoring.

Long-Acting Basal Insulins

Modern basal insulins are engineered to release at a slow, flat rate for roughly a full day or longer. Five products matter:

The practical question most patients ask is: "Does it matter which one I am on?" For a person whose numbers are stable on Lantus or Basaglar, it does not matter. For a person waking up low at 3 a.m. despite careful dosing, switching to Toujeo or Tresiba often fixes it. For a person who works rotating shifts or travels across time zones, Tresiba's flatness is a real quality-of-life gain.

Premixed Insulins

Premixed insulins combine a basal and a bolus in one pen. Common ratios:

Premixed regimens are usually twice daily, before breakfast and before dinner. They are simpler than basal-bolus — two injections instead of five — and they suit people with steady schedules and steady meal sizes: older adults, people with cognitive impairment, people whose caregivers do the dosing. The trade-off is flexibility. You cannot separately adjust the basal when you are sick or the bolus when you skip a meal. For type 1 diabetes, premixed is generally not adequate. For stable type 2, it can be an excellent pragmatic choice.

Pump-Compatible Insulins

Insulin pumps deliver continuous subcutaneous infusion through a small cannula you change every 2 to 3 days. Only rapid-acting analogs are used in pumps: Humalog, Novolog, Fiasp, and Lyumjev. Apidra is FDA-approved for pump use but tends to crystallize in tubing over 48 hours and is less popular. Regular insulin is not used in modern pumps because its long tail destroys the math of automated dosing.

Some pump users prefer Fiasp or Lyumjev for the faster meal response; others find the ultra-rapid formulations more likely to cause infusion-set irritation and stick with Humalog or Novolog. This is an individual trial.

The Basal-Bolus MDI Regimen

MDI means multiple daily injections. It is the gold-standard regimen for type 1 diabetes when not using a pump, and an excellent regimen for insulin-requiring type 2. The structure is:

Four to five injections a day sounds like a lot until you realize that the pen needle is 4 mm long and thinner than a human hair. Most patients describe the injections as painless within two weeks. The tight glucose control that basal-bolus enables is worth the learning curve.

Pump Therapy and AID Systems

An insulin pump replaces the basal insulin (with a programmable micro-drip of rapid insulin delivered every few minutes) and replaces mealtime pens (you push buttons instead). Since about 2020, pumps have evolved into automated insulin delivery (AID) systems — also called hybrid closed-loop systems — that read your continuous glucose monitor (CGM) in real time and adjust the basal rate minute-by-minute.

The current commercial options in the U.S.:

AID systems reliably lift time-in-range (70–180 mg/dL) by 10 to 20 percentage points compared with MDI in most studies, with less nocturnal hypoglycemia. They are not magic — you still bolus for meals (except on iLet), still change sites, still replace CGM sensors — but they dramatically reduce the mental load of T1D.

Carb Counting Basics

Carb counting means measuring the grams of carbohydrate in each meal so you can calculate the correct bolus. In practice you use three tools in combination:

Protein and fat matter too. A pure-carb meal (toast with jam) hits the bloodstream within 30 minutes. A high-fat, high-protein meal (pizza, lasagna, cheeseburger and fries) releases glucose over 4 to 6 hours — the pizza effect. Pump users handle this with extended or combo boluses. MDI users either split the bolus (half before the meal, half at the 90-minute mark) or add a small dose of Regular insulin. Every T1D eventually learns which foods do this to them. Dinner leftovers for lunch usually behave differently than the same food fresh — another quirk to log.

I:C Ratio, Correction Factor, and the 500/1800 Rules

Two numbers drive every bolus calculation:

Insulin-to-carb ratio (I:C) is how many grams of carbohydrate one unit of rapid insulin covers. If your I:C is 1:10, you take 1 unit per 10 grams of carb. A 60-gram meal = 6 units.

The classic starting estimate is the 500 rule: divide 500 by your total daily dose (TDD) of insulin. If you take 50 units a day total, your I:C is about 500 ÷ 50 = 10, so 1 unit per 10 g carb. For Regular insulin instead of rapid, use the 450 rule.

Correction factor (CF), also called insulin sensitivity factor (ISF), is how much one unit of rapid insulin will drop your glucose. If your CF is 50, one unit lowers blood sugar by 50 mg/dL. A reading of 220 with a target of 120 means a 100-point drop needed = 2 units of correction.

Starting estimate: the 1800 rule (some endocrinologists use 1700). Divide 1800 by your TDD. For a 50-unit-per-day person: 1800 ÷ 50 = 36 mg/dL per unit.

A pre-meal dose is the sum: carb dose + correction dose. If your meal has 60 g carb and your pre-meal glucose is 220 with a target of 120, you give 6 + 2 = 8 units.

These are starting points. Real I:C and CF vary by time of day — most people are more insulin-resistant in the morning — by menstrual cycle, by exercise, by illness, and by stress. Pumps let you program three or four different ratios across the day. MDI users can simply note that, say, breakfast needs 1:8 while dinner needs 1:12.

Basal Dosing and Basal Testing

Basal insulin should cover your glucose between meals without pushing you low. The usual split is 40 to 50% of total daily dose as basal, with the rest as mealtime bolus. For a 50-unit-per-day person that means roughly 20 to 25 units of long-acting.

To confirm the basal dose is right, endocrinologists use basal testing. The method: skip a meal (say, lunch), do not bolus, and check glucose every 2 to 3 hours for the next 6 hours. If glucose stays flat within about 30 mg/dL of starting, your basal in that window is correct. If it drifts up, basal is too low. If it drifts down, basal is too high. Repeat across breakfast, lunch, and dinner windows on different days to map the whole 24-hour profile. CGM users can do this passively by scanning the CGM line during accidental skipped meals.

Adjust no faster than 10% every 3 days. Basal insulins take 3 to 5 days to reach a new steady state, so faster adjustments chase ghosts.

Dawn Phenomenon vs Somogyi

Many people with diabetes wake up with higher glucose than they went to bed with. The two classic explanations:

Somogyi is much rarer than it used to be thought — modern CGM data suggest dawn phenomenon accounts for the vast majority of morning highs. But the distinction matters because the two conditions need opposite adjustments. CGM answers the question in one night.

Sick-Day Rules

Infections, fevers, vomiting, and surgery all push glucose up and, in type 1 diabetes, can push ketones up fast. Core sick-day principles:

Exercise Adjustments

Exercise is one of the most powerful glucose-lowering tools you have, and also one of the most common causes of hypoglycemia. Three patterns matter:

Carry fast carbs (glucose tabs, juice box, Smarties) to every workout. CGM users set a low-alert threshold around 90 mg/dL during exercise so they get warning before symptoms.

Hypoglycemia Prevention in Brittle T1D

Some people, especially long-duration T1D patients, develop hypoglycemia unawareness — they no longer feel the shakiness, sweating, or hunger that warn of a low. Numbers can drop into the 40s before they notice. The standard toolkit:

Insurance and Cost Realities

U.S. insulin pricing has been a national scandal for a decade. The picture in 2026:

If you are staring down an unaffordable insulin bill: call the manufacturer's patient assistance program (Lilly Cares, NovoCare, Sanofi Patient Connection) before you cut doses. Most will provide free insulin to uninsured patients below about 400% of the federal poverty line. Never ration insulin silently — the mortality risk is real and help exists.

Key Research Papers

Research Papers

For further reading, the following PubMed topic searches return current peer-reviewed work on insulin pharmacology, dosing strategy, and automated delivery:

  1. Insulin analog pharmacokinetics
  2. Basal-bolus therapy in type 1 diabetes
  3. Insulin degludec and nocturnal hypoglycemia
  4. Automated insulin delivery and hybrid closed-loop systems
  5. Insulin-to-carbohydrate ratio methodology
  6. Dawn phenomenon in diabetes
  7. Hypoglycemia unawareness in type 1 diabetes
  8. Inhaled insulin (Afrezza) clinical outcomes
  9. Insulin biosimilars and interchangeability

Connections

Back to Table of Contents